IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0313443.html
   My bibliography  Save this article

Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis

Author

Listed:
  • Hui-Bo Yu
  • Jia-Qi Hu
  • Bao-Jin Han
  • Yan-Yuan Du
  • Shun-Tai Chen
  • Xin Chen
  • Hong-Tai Xiong
  • Jin Gao
  • Hong-Gang Zheng

Abstract

Background: This study aimed to investigate the therapeutic efficacy and safety of Traditional medicine preparations (TMPs) given in combination with vascular endothelial growth factor receptor (VEGFR)-associated multi-targeted tyrosine kinase inhibitors (TKIs) for the treatment of middle to advanced-stage primary liver cancer (PLC). Methods: This systematic literature survey employed 10 electronic databases and 2 clinical trial registration platforms to identify relevant studies on the use of TMPs + VEGFR-TKIs to treat patients with middle-advanced PLC. Furthermore, a meta-analysis was performed following the PRISMA guidelines using the risk ratio (RR) at 95% confidence intervals (CI) or standardized mean difference as effect measures. Results: A total of 26 studies comprising 1678 middle-advanced PLC patients were selected. The meta-analysis revealed that compared with VEGFR-TKI mono-treatment, the co-therapy of TMPs + VEGFR-TKIs considerably enhanced the objective response rate (RR = 1.49, 95% CI: 1.31–1.69), disease control rate (RR = 1.23, 95% CI: 1.16–1.30), and one-year overall survival (RR = 1.49, 95% CI: 1.28–1.74). Furthermore, the co-therapy was associated with reduced incidences of liver dysfunction (RR = 0.64, 95% CI: 0.45–0.91), proteinuria (RR = 0.43, 95% CI: 0.24–0.75), hypertension (RR = 0.66, 95% CI: 0.53–0.83), hand-foot skin reactions (RR = 0.63, 95% CI: 0.49–0.80), myelosuppression (RR = 0.63, 95% CI: 0.46–0.87), and gastrointestinal reactions (RR = 0.64, 95% CI: 0.45–0.92). Moreover, the co-therapy indicated no increase in the incidences of rash and fatigue. Conclusion: This systematic analysis revealed that co-therapy with TMPs + VEGFR-TKIs has a higher effectiveness and safety profile for treating middle-advanced PLC patients. However, further validation using randomized control trials is required. PROSPERO registration no: CRD42022350634.

Suggested Citation

  • Hui-Bo Yu & Jia-Qi Hu & Bao-Jin Han & Yan-Yuan Du & Shun-Tai Chen & Xin Chen & Hong-Tai Xiong & Jin Gao & Hong-Gang Zheng, 2024. "Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 19(11), pages 1-32, November.
    • Handle: RePEc:plo:pone00:0313443
    DOI: 10.1371/journal.pone.0313443
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313443
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0313443&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0313443?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0313443. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.